JKJacob J. E. Koopman

Jacob J. E. Koopman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jacob J. E. Koopman has a total of 89 co-authors. Here are the top co-authors by number of shared publications:

  • David van Bodegom

    Department of Public health and Primary Care, Leiden University Medical Centre, Leiden, The Netherlands

    9 shared publications
  • Rudi G. J. Westendorp

    Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands; Leyden Academy on Vitality and Ageing, Leiden, The Netherlands; Department of Clinical Laboratory Sciences, School of Medicine and Health Sciences, University for Development Studies, Tamale, Ghana; Department of Public Health and Center of Healthy Aging, University of Copenhagen, Copenhagen, Denmark

    4 shared publications
  • Diana van Heemst

    Section of Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands

    3 shared publications
  • Karen H. Costenbader

    Harvard Medical School, Boston, MA

    3 shared publications
  • Anneke Kramer

    ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands

    2 shared publications
  • Gearoid M McMahon

    Division of Renal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

    2 shared publications

Latest Publications

  • Scoping Review of Human Longitudinal Studies of Biomarkers Associated with Risk of Developing Systemic Lupus Erythematosus (SLE) to Inform the Development of a Novel SLE Risk Stratification Index

    by Alice Horisberger, Youngmin Kim, Jeong Yee, Jacob J.E. Koopman, Sindhu R Johnson, Alí Duarte‐García, Zahi Touma, Marta Mosca, Karen H. Costenbader

    Objective: SLE is often preceded by a preclinical phase in which autoantibodies and other biomarkers are detectable, offering an opportunity to identify at‐risk individuals for early monitoring and testing interventions to halt progression. To inform an effort to develop SLE risk‐stratification criteria, we conducted a scoping review of longitudinal human studies of biomarkers measured before SLE onset. Methods: Following PRISMA‐ScR, we searched three databases and used a Population, Exposure, Comparator, Outcome framework to select longitudinal studies in which biomarkers were measured before an incident diagnosis or classification of SLE. Study characteristics, biomarkers, and outcomes were extracted from included studies. Results: We included 59 original studies and two meta‐analyses including heterogeneous at‐risk populations, in which the proportion progressing to SLE varied widely. Most evidence concerned conventional serological markers, whereas interferon and cytokine signatures, proteomic panels, and genetic risk scores were examined in fewer, recent cohorts. Few biomarkers were studied across multiple populations or with comparable follow‐up, outcome definitions, and analytic methods, and most associations came from single studies without external validation. Longitudinal biomarker trajectories before onset were rarely characterized, and non‐European populations were under‐represented. Conclusion: his review maps the breadth of candidate biomarkers associated with the risk of developing SLE and the heterogeneity of the evidence supporting them. Building a clinically useful SLE risk‐stratification index will need a shared definition of the at‐risk state, and prospective studies that follow biomarkers over time, in populations from broader geographical regions.

  • Open Access

    Implications of 2023 ACR/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus

    by B.C. Geertsema-Hoeve, M.C. Stam-Slob, M. Bijl, J. Eikenboom, C.J.M. Frijns, R.J. Goekoop, L.L. van Den Hoogen, A. Huisman, A.J.G. Jansen, J. Kooiman, et al.

  • Open Access

    Real‐World Effectiveness and Safety of JAK Inhibitors in Atopic Dermatitis: A Systematic Review and Meta‐Analysis

    by Yunha Kim, Gayeong Seo, Jacob J. E. Koopman, Jeong Yee

    Objective: The aim of this study is to evaluate the effectiveness and safety of JAK inhibitors in patients with moderate to severe atopic dermatitis by performing a systematic review and meta‐analysis using data from studies in real‐world settings. Design: Systematic review and meta‐analysis. Pooled estimates for effectiveness and safety were assessed using the Freeman–Tukey Double ArcSine method. Statistical heterogeneity was assessed using I 2 statistics. A random‐effects model (DerSimonian‐Laird method) was applied to consider the heterogeneity within and between studies and to give a more conservative estimate. The study quality assessment tools developed by the National Heart, Lung, and Blood Institute were used. Data Source: Relevant studies were searched in March 2025 using four databases: PubMed, Embase, Scopus, and Web of Science. Eligibility Criteria: Studies evaluating the effectiveness or safety of systemic JAK inhibitors among patients with moderate to severe atopic dermatitis in a real‐world setting were included. Results: A total of 50 studies were included in this review. Regarding their effectiveness, the pooled estimates with a 95% CI of Eczema Area and Severity Index (EASI)‐75 were 44% (34%–55%), 45% (28%–62%), 59% (51%–66%), 73% (64%–81%), 70% (57%–81%), and 86% (72%–96%) at 4, 8, 12, 16, 24, and 52 weeks. For safety, the most common adverse events were acne (16%), followed by increased creatine phosphokinase levels (13%) and increased lipids (12%). Conclusion: Our meta‐analysis of JAK inhibitors in patients with atopic dermatitis demonstrated that the overall outcomes from real‐world settings are comparable to those from clinical trials. Systematic Review Registration: Protocol Registration: PROSPERO CRD42024569258.


  • Environmental Risk Factors for Systemic Lupus Erythematosus Through the Lens of Social Determinants of Health

    by Youngmin Kim, Jacob J. E. Koopman, May Choi, Candace H. Feldman, Karen H. Costenbader

    Systemic lupus erythematosus (SLE) is a serious multisystem autoimmune disease, marked by alarming sociodemographic inequities. In the United States and around the world, social disadvantage is strongly tied to higher prevalence, more severe disease, and poorer outcomes. A growing list of environmental exposures that contribute to the risk and incidence of SLE have been investigated, and many are now established. However, these environmental exposures—including exposure to air pollution and other contaminants, lifestyle and behavioral factors, and psychologic stress and distress—are not evenly distributed in any population. Individuals of lower socioeconomic status and historically minoritized groups suffer from an imbalanced burden of adverse environmental exposures. In research, clinical practice, and policy making, the strong association of social determinants of health (SDoH) with these exposures has not been given adequate spotlight. In this narrative review, we examine known associations between environmental exposures and SLE risk through the lens of SDoH, laying the foundation for future research and policies to target the environmental risk factors for SLE with awareness of the populations disproportionately affected and the contributing SDoH.


  • Open Access

    From machine learning to clinical practice: phenotypic clusters of anti-MDA5 antibody-positive dermatomyositis

    by Jacob J E Koopman, Katherine A Buhler, May Y Choi

    A recent review written by McLeish et al. elegantly explains the use of machine learning techniques for the diagnosis, prognosis and treatment of idiopathic inflammatory myopathies (IIMs) [ 1]. The usefulness in clinical practice of such techniques, however, remains uncertain, as the authors themselves admit.


  • Associations between renal deposits of complement factors, disease activity and loss of renal function in lupus nephritis

    by Jacob J E Koopman, Helmut G Rennke, Gearoid M McMahon, Sushrut S Waikar, Karen H Costenbader


  • Open Access

    Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys

    by Jacob J. E. Koopman, Mieke F. van Essen, Helmut G. Rennke, Aiko P. J. de Vries, Cees van Kooten

    The membrane attack complex—also known as C5b-9—is the end-product of the classical, lectin, and alternative complement pathways. It is thought to play an important role in the pathogenesis of various kidney diseases by causing cellular injury and tissue inflammation, resulting in sclerosis and fibrosis. These deleterious effects are, consequently, targeted in the development of novel therapies that inhibit the formation of C5b-9, such as eculizumab. To clarify how C5b-9 contributes to kidney disease and to predict which patients benefit from such therapy, knowledge on deposition of C5b-9 in the kidney is essential. Because immunohistochemical staining of C5b-9 has not been routinely conducted and never been compared across studies, we provide a review of studies on deposition of C5b-9 in healthy and diseased human kidneys. We describe techniques to stain deposits and compare the occurrence of deposits in healthy kidneys and in a wide spectrum of kidney diseases, including hypertensive nephropathy, diabetic nephropathy, membranous nephropathy, IgA nephropathy, lupus nephritis, C3 glomerulopathy, and thrombotic microangiopathies such as the atypical hemolytic uremic syndrome, vasculitis, interstitial nephritis, acute tubular necrosis, kidney tumors, and rejection of kidney transplants. We summarize how these deposits are related with other histological lesions and clinical characteristics. We evaluate the prognostic relevance of these deposits in the light of possible treatment with complement inhibitors.


  • A Comparison of Different Estimates of Albuminuria in Association with Mortality in Epidemiologic Research

    by Jacob J.E. Koopman, Rebecca Scherzer, Joachim H. Ix, Michael G. Shlipak, Sushrut S. Waikar


  • Open Access

    Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis

    by Jacob J E Koopman, Helmut G Rennke, Cianna Leatherwood, Cameron B Speyer, Kristin D’sIlva, Gearoid M McMahon, Sushrut S Waikar, Karen H Costenbader

    Objective: Lupus nephritis (LN) increases the risks of end-stage renal disease (ESRD) and death, but these risks are difficult to estimate. Since complement factors play an essential role in the pathogenesis and are deposited in the kidneys as C1q and C3, we studied whether these deposits predict ESRD and death in patients with LN. Methods: We collected demographic, clinical and pathological data from 183 adult patients with LN classes II–V diagnosed with a first native kidney biopsy. Pathological data included the localization and intensity of immunofluorescence staining of C1q and C3. We obtained dates of incident ESRD and death from the United States Renal Data System and National Death Index, respectively, and evaluated survival curves and hazard ratios for ESRD and death as a composite outcome and as separate outcomes. Results: The presence and intensity of deposits of C1q and C3 in glomeruli, tubular walls and vascular walls differed between classes and were associated with known unfavourable prognostic factors, such as hypertension, hypoalbuminemia and hypocomplementemia. However, over a median follow-up of 7.5 years, their presence and intensity were associated with neither survival free of ESRD and death nor hazard ratios for ESRD and death. Conclusion: Renal deposits of complement factors did not predict ESRD and death in patients with LN.